|
1.
|
Lewis MM, Du G, Kidacki M, Patel N, Shaffer ML, Mailman RB, Huang X. Higher iron in the red nucleus marks Parkinson's dyskinesia. Neurobiol Aging. 2013 May; 34(5):1497-503.
|
|
|
|
|
2.
|
Du G, Lewis MM, Shaffer ML, Chen H, Yang QX, Mailman RB, Huang X. Serum cholesterol and nigrostriatal R2* values in Parkinson's disease. PLoS One. 2012; 7(4):e35397.
|
|
|
|
|
3.
|
Fowler JC, Bhattacharya S, Urban JD, Vaidehi N, Mailman RB. Receptor conformations involved in dopamine D(2L) receptor functional selectivity induced by selected transmembrane-5 serine mutations. Mol Pharmacol. 2012 Jun; 81(6):820-31.
|
|
|
|
|
4.
|
Boyd KN, Mailman RB. Dopamine receptor signaling and current and future antipsychotic drugs. Handb Exp Pharmacol. 2012; (212):53-86.
|
|
|
|
|
5.
|
Huang X, Auinger P, Eberly S, Oakes D, Schwarzschild M, Ascherio A, Mailman R, Chen H. Serum cholesterol and the progression of Parkinson's disease: results from DATATOP. PLoS One. 2011; 6(8):e22854.
|
|
|
|
|
6.
|
Gao J, Huang X, Park Y, Liu R, Hollenbeck A, Schatzkin A, Mailman RB, Chen H. Apolipoprotein E genotypes and the risk of Parkinson disease. Neurobiol Aging. 2011 Nov; 32(11):2106.e1-6.
|
|
|
|
|
7.
|
Lewis MM, Du G, Sen S, Kawaguchi A, Truong Y, Lee S, Mailman RB, Huang X. Differential involvement of striato- and cerebello-thalamo-cortical pathways in tremor- and akinetic/rigid-predominant Parkinson's disease. Neuroscience. 2011 Mar 17; 177:230-9.
|
|
|
|
|
8.
|
Chen H, Huang X, Guo X, Mailman RB, Park Y, Kamel F, Umbach DM, Xu Q, Hollenbeck A, Schatzkin A, Blair A. Smoking duration, intensity, and risk of Parkinson disease. Neurology. 2010 Mar 16; 74(11):878-84.
|
|
|
|
|
9.
|
Huang X, Chen H, Petrovitch H, Mailman R, Ross W. Reply: Plasma cholesterol and Parkinson's disease: Is the puzzle only apparent? Mov Disord. 2010 Jan 15; 25(1):137.
|
|
|
|
|
10.
|
Mailman RB, Murthy V. Third generation antipsychotic drugs: partial agonism or receptor functional selectivity? Curr Pharm Des. 2010; 16(5):488-501.
|
|
|
|
|
11.
|
Mailman RB, Murthy V. Ligand functional selectivity advances our understanding of drug mechanisms and drug discovery. Neuropsychopharmacology. 2010 Jan; 35(1):345-6.
|
|
|
|
|
12.
|
Lewis MM, Smith AB, Styner M, Gu H, Poole R, Zhu H, Li Y, Barbero X, Gouttard S, McKeown MJ, Mailman RB, Huang X. Asymmetrical lateral ventricular enlargement in Parkinson's disease. Eur J Neurol. 2009 Apr; 16(4):475-81.
|
|
|
|
|
13.
|
Brown JT, Kant A, Mailman RB. Rapid, semi-automated, and inexpensive radioimmunoassay of cAMP: application in GPCR-mediated adenylate cyclase assays. J Neurosci Methods. 2009 Mar 15; 177(2):261-6.
|
|
|
|
|
14.
|
Huang X, Abbott RD, Petrovitch H, Mailman RB, Ross GW. Low LDL cholesterol and increased risk of Parkinson's disease: prospective results from Honolulu-Asia Aging Study. Mov Disord. 2008 May 15; 23(7):1013-8.
|
|
|
|
|
15.
|
Mailman RB. GPCR functional selectivity has therapeutic impact. Trends Pharmacol Sci. 2007 Aug; 28(8):390-6.
|
|
|
|
|
16.
|
Mu Q, Johnson K, Morgan PS, Grenesko EL, Molnar CE, Anderson B, Nahas Z, Kozel FA, Kose S, Knable M, Fernandes P, Nichols DE, Mailman RB, George MS. A single 20 mg dose of the full D1 dopamine agonist dihydrexidine (DAR-0100) increases prefrontal perfusion in schizophrenia. Schizophr Res. 2007 Aug; 94(1-3):332-41.
|
|
|
|
|
17.
|
Lewis MM, Slagle CG, Smith AB, Truong Y, Bai P, McKeown MJ, Mailman RB, Belger A, Huang X. Task specific influences of Parkinson's disease on the striato-thalamo-cortical and cerebello-thalamo-cortical motor circuitries. Neuroscience. 2007 Jun 15; 147(1):224-35.
|
|
|
|
|
18.
|
George MS, Molnar CE, Grenesko EL, Anderson B, Mu Q, Johnson K, Nahas Z, Knable M, Fernandes P, Juncos J, Huang X, Nichols DE, Mailman RB. A single 20 mg dose of dihydrexidine (DAR-0100), a full dopamine D1 agonist, is safe and tolerated in patients with schizophrenia. Schizophr Res. 2007 Jul; 93(1-3):42-50.
|
|
|
|
|
19.
|
Huang X, Chen H, Miller WC, Mailman RB, Woodard JL, Chen PC, Xiang D, Murrow RW, Wang YZ, Poole C. Lower low-density lipoprotein cholesterol levels are associated with Parkinson's disease. Mov Disord. 2007 Feb 15; 22(3):377-81.
|
|
|
|
|
20.
|
Mailman RB, Huang X. Dopamine receptor pharmacology. Handb Clin Neurol. 2007; 83:77-105.
|
|
|
|
|
21.
|
Ryman-Rasmussen JP, Griffith A, Oloff S, Vaidehi N, Brown JT, Goddard WA, Mailman RB. Functional selectivity of dopamine D1 receptor agonists in regulating the fate of internalized receptors. Neuropharmacology. 2007 Feb; 52(2):562-75.
|
|
|
|
|
22.
|
Leonard SK, Ferry-Leeper P, Mailman RB. Low affinity binding of the classical D1 antagonist SCH23390 in rodent brain: potential interaction with A2A and D2-like receptors. Brain Res. 2006 Oct 30; 1117(1):25-37.
|
|
|
|
|
23.
|
Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, Javitch JA, Roth BL, Christopoulos A, Sexton PM, Miller KJ, Spedding M, Mailman RB. Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther. 2007 Jan; 320(1):1-13.
|
|
|
|
|
24.
|
Lewis MM, Huang X, Nichols DE, Mailman RB. D1 and functionally selective dopamine agonists as neuroprotective agents in Parkinson's disease. CNS Neurol Disord Drug Targets. 2006 Jun; 5(3):345-53.
|
|
|
|
|
25.
|
Urban JD, Vargas GA, von Zastrow M, Mailman RB. Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways. Neuropsychopharmacology. 2007 Jan; 32(1):67-77.
|
|
|
|
|
26.
|
Oloff S, Mailman RB, Tropsha A. Application of validated QSAR models of D1 dopaminergic antagonists for database mining. J Med Chem. 2005 Nov 17; 48(23):7322-32.
|
|
|
|
|
27.
|
Padilla S, Marshall RS, Hunter DL, Oxendine S, Moser VC, Southerland SB, Mailman RB. Neurochemical effects of chronic dietary and repeated high-level acute exposure to chlorpyrifos in rats. Toxicol Sci. 2005 Nov; 88(1):161-71.
|
|
|
|
|
28.
|
Ryman-Rasmussen JP, Nichols DE, Mailman RB. Differential activation of adenylate cyclase and receptor internalization by novel dopamine D1 receptor agonists. Mol Pharmacol. 2005 Oct; 68(4):1039-48.
|
|
|
|
|
29.
|
Gay EA, Urban JD, Nichols DE, Oxford GS, Mailman RB. Functional selectivity of D2 receptor ligands in a Chinese hamster ovary hD2L cell line: evidence for induction of ligand-specific receptor states. Mol Pharmacol. 2004 Jul; 66(1):97-105.
|
|
|
|
|
30.
|
Grubbs RA, Lewis MM, Owens-Vance C, Gay EA, Jassen AK, Mailman RB, Nichols DE. 8,9-dihydroxy-1,2,3,11b-tetrahydrochromeno[4,3,2,-de]isoquinoline (dinoxyline), a high affinity and potent agonist at all dopamine receptor isoforms. Bioorg Med Chem. 2004 Mar 15; 12(6):1403-12.
|
|
|
|
|
31.
|
Sit SY, Xie K, Jacutin-Porte S, Boy KM, Seanz J, Taber MT, Gulwadi AG, Korpinen CD, Burris KD, Molski TF, Ryan E, Xu C, Verdoorn T, Johnson G, Nichols DE, Mailman RB. Synthesis and SAR exploration of dinapsoline analogues. Bioorg Med Chem. 2004 Feb 15; 12(4):715-34.
|
|
|
|
|
32.
|
Leonard SK, Anderson CM, Lachowicz JE, Schulz DW, Kilts CD, Mailman RB. Amygdaloid D1 receptors are not linked to stimulation of adenylate cyclase. Synapse. 2003 Dec 15; 50(4):320-33.
|
|
|
|
|
33.
|
Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, Roth BL, Mailman R. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology. 2003 Aug; 28(8):1400-11.
|
|
|
|
|
34.
|
Qandil AM, Lewis MM, Jassen A, Leonard SK, Mailman RB, Nichols DE. Synthesis and pharmacological evaluation of substituted naphth[1,2,3-de]isoquinolines (dinapsoline analogues) as D1 and D2 dopamine receptor ligands. Bioorg Med Chem. 2003 Apr 3; 11(7):1451-64.
|
|
|
|
|
35.
|
Andersson C, Hamer RM, Lawler CP, Mailman RB, Lieberman JA. Striatal volume changes in the rat following long-term administration of typical and atypical antipsychotic drugs. Neuropsychopharmacology. 2002 Aug; 27(2):143-51.
|
|
|
|
|
36.
|
Mottola DM, Kilts JD, Lewis MM, Connery HS, Walker QD, Jones SR, Booth RG, Hyslop DK, Piercey M, Wightman RM, Lawler CP, Nichols DE, Mailman RB. Functional selectivity of dopamine receptor agonists. I. Selective activation of postsynaptic dopamine D2 receptors linked to adenylate cyclase. J Pharmacol Exp Ther. 2002 Jun; 301(3):1166-78.
|
|
|
|
|
37.
|
Kilts JD, Connery HS, Arrington EG, Lewis MM, Lawler CP, Oxford GS, O'Malley KL, Todd RD, Blake BL, Nichols DE, Mailman RB. Functional selectivity of dopamine receptor agonists. II. Actions of dihydrexidine in D2L receptor-transfected MN9D cells and pituitary lactotrophs. J Pharmacol Exp Ther. 2002 Jun; 301(3):1179-89.
|
|
|
|
|
38.
|
Mailman R, Huang X, Nichols DE. Parkinson's disease and D1 dopamine receptors. Curr Opin Investig Drugs. 2001 Nov; 2(11):1582-91.
|
|
|
|
|
39.
|
Miyamoto S, Mailman RB, Lieberman JA, Duncan GE. Blunted brain metabolic response to ketamine in mice lacking D(1A) dopamine receptors. Brain Res. 2001 Mar 16; 894(2):167-80.
|
|
|
|
|
40.
|
Montague DM, Striplin CD, Overcash JS, Drago J, Lawler CP, Mailman RB. Quantification of D1B(D5) receptors in dopamine D1A receptor-deficient mice. Synapse. 2001 Mar 15; 39(4):319-22.
|
|
|
|
|
41.
|
Gulwadi AG, Korpinen CD, Mailman RB, Nichols DE, Sit SY, Taber MT. Dinapsoline: characterization of a D1 dopamine receptor agonist in a rat model of Parkinson's disease. J Pharmacol Exp Ther. 2001 Feb; 296(2):338-44.
|
|
|
|
|
42.
|
Huang X, Lawler CP, Lewis MM, Nichols DE, Mailman RB. D1 dopamine receptors. Int Rev Neurobiol. 2001; 48:65-139.
|
|
|
|
|
43.
|
Montague DM, Lawler CP, Mailman RB, Gilmore JH. Developmental regulation of the dopamine D1 receptor in human caudate and putamen. Neuropsychopharmacology. 1999 Nov; 21(5):641-9.
|
|
|
|
|
44.
|
Hoffman B, Cho SJ, Zheng W, Wyrick S, Nichols DE, Mailman RB, Tropsha A. Quantitative structure-activity relationship modeling of dopamine D(1) antagonists using comparative molecular field analysis, genetic algorithms-partial least-squares, and K nearest neighbor methods. J Med Chem. 1999 Aug 26; 42(17):3217-26.
|
|
|
|
|
45.
|
Lawler CP, Prioleau C, Lewis MM, Mak C, Jiang D, Schetz JA, Gonzalez AM, Sibley DR, Mailman RB. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology. 1999 Jun; 20(6):612-27.
|
|
|
|
|
46.
|
Doll MK, Nichols DE, Kilts JD, Prioleau C, Lawler CP, Lewis MM, Mailman RB. Synthesis and dopaminergic properties of benzo-fused analogues of quinpirole and quinelorane. J Med Chem. 1999 Mar 11; 42(5):935-40.
|
|
|
|
|
47.
|
Lieberman JA, Mailman RB, Duncan G, Sikich L, Chakos M, Nichols DE, Kraus JE. Serotonergic basis of antipsychotic drug effects in schizophrenia. Biol Psychiatry. 1998 Dec 1; 44(11):1099-117.
|
|
|
|
|
48.
|
Duncan GE, Leipzig JN, Mailman RB, Lieberman JA. Differential effects of clozapine and haloperidol on ketamine-induced brain metabolic activation. Brain Res. 1998 Nov 23; 812(1-2):65-75.
|
|
|
|
|
49.
|
Smith DR, Striplin CD, Geller AM, Mailman RB, Drago J, Lawler CP, Gallagher M. Behavioural assessment of mice lacking D1A dopamine receptors. Neuroscience. 1998 Sep; 86(1):135-46.
|
|
|
|
|
50.
|
Mailman RB, Nichols DE. Dopamine D1 receptor agonists as antiparkinson drugs. Trends Pharmacol Sci. 1998 Jul; 19(7):255-6.
|
|
|
|
|
51.
|
Lewis MM, Watts VJ, Lawler CP, Nichols DE, Mailman RB. Homologous desensitization of the D1A dopamine receptor: efficacy in causing desensitization dissociates from both receptor occupancy and functional potency. J Pharmacol Exp Ther. 1998 Jul; 286(1):345-53.
|
|
|
|
|
52.
|
Monte AP, Marona-Lewicka D, Lewis MM, Mailman RB, Wainscott DB, Nelson DL, Nichols DE. Substituted naphthofurans as hallucinogenic phenethylamine-ergoline hybrid molecules with unexpected muscarinic antagonist activity. J Med Chem. 1998 Jun 4; 41(12):2134-45.
|
|
|
|
|
53.
|
Bunin MA, Prioleau C, Mailman RB, Wightman RM. Release and uptake rates of 5-hydroxytryptamine in the dorsal raphe and substantia nigra reticulata of the rat brain. J Neurochem. 1998 Mar; 70(3):1077-87.
|
|
|
|
|
54.
|
Lieberman JA, Mailman R. Decline of dopamine: effects of age and acute neuroleptic challenge. Am J Psychiatry. 1998 Mar; 155(3):319-23.
|
|
|
|
|
55.
|
Andersson C, Chakos M, Mailman R, Lieberman J. Emerging roles for novel antipsychotic medications in the treatment of schizophrenia. Psychiatr Clin North Am. 1998 Mar; 21(1):151-79.
|
|
|
|
|
56.
|
Negash K, Nichols DE, Watts VJ, Mailman RB. Further definition of the D1 dopamine receptor pharmacophore: synthesis of trans-6,6a,7,8,9,13b-hexahydro-5H-benzo[d]naphth[2,1-b]azepines as rigid analogues of beta-phenyldopamine. J Med Chem. 1997 Jul 4; 40(14):2140-7.
|
|
|
|
|
57.
|
Smith HP, Nichols DE, Mailman RB, Lawler CP. Locomotor inhibition, yawning and vacuous chewing induced by a novel dopamine D2 post-synaptic receptor agonist. Eur J Pharmacol. 1997 Mar 26; 323(1):27-36.
|
|
|
|
|
58.
|
Walker QD, Mailman RB. Triadimefon and triadimenol: effects on monoamine uptake and release. Toxicol Appl Pharmacol. 1996 Aug; 139(2):227-33.
|
|
|
|
|
59.
|
Ghosh D, Snyder SE, Watts VJ, Mailman RB, Nichols DE. 9-Dihydroxy-2,3,7,11b-tetrahydro-1H-naph[1,2,3-de]isoquinoline: a potent full dopamine D1 agonist containing a rigid-beta-phenyldopamine pharmacophore. J Med Chem. 1996 Jan 19; 39(2):549-55.
|
|
|
|
|
60.
|
Mottola DM, Laiter S, Watts VJ, Tropsha A, Wyrick SD, Nichols DE, Mailman RB. Conformational analysis of D1 dopamine receptor agonists: pharmacophore assessment and receptor mapping. J Med Chem. 1996 Jan 5; 39(1):285-96.
|
|
|
|
|
61.
|
Lawler CP, Gilmore JH, Watts VJ, Walker QD, Southerland SB, Cook LL, Mathis CA, Mailman RB. Interhemispheric modulation of dopamine receptor interactions in unilateral 6-OHDA rodent model. Synapse. 1995 Dec; 21(4):299-311.
|
|
|
|
|
62.
|
Watts VJ, Lawler CP, Gonzales AJ, Zhou QY, Civelli O, Nichols DE, Mailman RB. Spare receptors and intrinsic activity: studies with D1 dopamine receptor agonists. Synapse. 1995 Oct; 21(2):177-87.
|
|
|
|
|
63.
|
Wyrick SD, Booth RG, Myers AM, Owens CE, Bucholtz EC, Hooper PC, Kula NS, Baldessarini RJ, Mailman RB. 1-Phenyl-3-amino-1,2,3,4-tetrahydronaphthalenes and related derivatives as ligands for the neuromodulatory sigma 3 receptor: further structure-activity relationships. J Med Chem. 1995 Sep 15; 38(19):3857-64.
|
|
|
|
|
64.
|
Knoerzer TA, Watts VJ, Nichols DE, Mailman RB. Synthesis and biological evaluation of a series of substituted benzo[a]phenanthridines as agonists at D1 and D2 dopamine receptors. J Med Chem. 1995 Aug 4; 38(16):3062-70.
|
|
|
|
|
65.
|
Gariépy JL, Gendreau PL, Mailman RB, Tancer M, Lewis MH. Rearing conditions alter social reactivity and D1 dopamine receptors in high- and low-aggressive mice. Pharmacol Biochem Behav. 1995 Aug; 51(4):767-73.
|
|
|
|
|
66.
|
Snyder SE, Aviles-Garay FA, Chakraborti R, Nichols DE, Watts VJ, Mailman RB. Synthesis and evaluation of 6,7-dihydroxy-2,3,4,8,9,13b-hexahydro-1H- benzo[6,7]cyclohepta[1,2,3-ef][3]benzazepine, 6,7-dihydroxy- 1,2,3,4,8,12b-hexahydroanthr[10,4a,4-cd]azepine, and 10-(aminomethyl)-9,10- dihydro-1,2-dihydroxyanthracene as conformationally restricted analogs of beta-phenyldopamine. J Med Chem. 1995 Jun 23; 38(13):2395-409.
|
|
|
|
|
67.
|
Gilmore JH, Watts VJ, Lawler CP, Noll EP, Nichols DE, Mailman RB. "Full" dopamine D1 agonists in human caudate: biochemical properties and therapeutic implications. Neuropharmacology. 1995 May; 34(5):481-8.
|
|
|
|
|
68.
|
Watts VJ, Lawler CP, Fox DR, Neve KA, Nichols DE, Mailman RB. LSD and structural analogs: pharmacological evaluation at D1 dopamine receptors. Psychopharmacology (Berl). 1995 Apr; 118(4):401-9.
|
|
|
|
|
69.
|
Blake BL, Rose RL, Mailman RB, Levi PE, Hodgson E. Metabolism of thioridazine by microsomal monooxygenases: relative roles of P450 and flavin-containing monooxygenase. Xenobiotica. 1995 Apr; 25(4):377-93.
|
|
|
|
|
70.
|
Heidenreich BA, Mailman RB, Nichols DE, Napier TC. Partial and full dopamine D1 agonists produce comparable increases in ventral pallidal neuronal activity: contribution of endogenous dopamine. J Pharmacol Exp Ther. 1995 Apr; 273(1):516-25.
|
|
|
|
|
71.
|
Brewster WK, Nichols DE, Watts VJ, Riggs RM, Mottola D, Mailman RB. Evaluation of cis- and trans-9- and 11-hydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridines as structurally rigid, selective D1 dopamine receptor ligands. J Med Chem. 1995 Jan 20; 38(2):318-27.
|
|
|
|
|
72.
|
Hudkins RL, Mailman RB, DeHaven-Hudkins DL. RLH-033, a novel, potent and selective ligand for the sigma 1 recognition site. Eur J Pharmacol. 1994 Dec 12; 271(1):235-6.
|
|
|
|
|
73.
|
Minor DL, Wyrick SD, Charifson PS, Watts VJ, Nichols DE, Mailman RB. Synthesis and molecular modeling of 1-phenyl-1,2,3,4-tetrahydroisoquinolines and related 5,6,8,9-tetrahydro-13bH-dibenzo[a,h]quinolizines as D1 dopamine antagonists. J Med Chem. 1994 Dec 9; 37(25):4317-28.
|
|
|
|
|
74.
|
Knoerzer TA, Nichols DE, Brewster WK, Watts VJ, Mottola D, Mailman RB. Dopaminergic benzo[a]phenanthridines: resolution and pharmacological evaluation of the enantiomers of dihydrexidine, the full efficacy D1 dopamine receptor agonist. J Med Chem. 1994 Jul 22; 37(15):2453-60.
|
|
|
|
|
75.
|
Hudkins RL, Mailman RB, DeHaven-Hudkins DL. Novel (4-phenylpiperidinyl)- and (4-phenylpiperazinyl)alkyl-spaced esters of 1-phenylcyclopentanecarboxylic acids as potent sigma-selective compounds. J Med Chem. 1994 Jun 24; 37(13):1964-70.
|
|
|
|
|
76.
|
Lewis MH, Gariépy JL, Gendreau P, Nichols DE, Mailman RB. Social reactivity and D1 dopamine receptors: studies in mice selectively bred for high and low levels of aggression. Neuropsychopharmacology. 1994 Apr; 10(2):115-22.
|
|
|
|
|
77.
|
Martin P, Ohno M, Southerland SB, Mailman RB, Suzuki K. Heterotypic sprouting of serotonergic forebrain fibers in the brindled mottled mutant mouse. Brain Res Dev Brain Res. 1994 Feb 18; 77(2):215-25.
|
|
|
|
|
78.
|
Tancer ME, Mailman RB, Stein MB, Mason GA, Carson SW, Golden RN. Neuroendocrine responsivity to monoaminergic system probes in generalized social phobia. Anxiety. 1994-1995; 1(5):216-23.
|
|
|
|
|
79.
|
Booth RG, Wyrick SD, Baldessarini RJ, Kula NS, Myers AM, Mailman RB. New sigma-like receptor recognized by novel phenylaminotetralins: ligand binding and functional studies. Mol Pharmacol. 1993 Dec; 44(6):1232-9.
|
|
|
|
|
80.
|
Watts VJ, Lawler CP, Gilmore JH, Southerland SB, Nichols DE, Mailman RB. Dopamine D1 receptors: efficacy of full (dihydrexidine) vs. partial (SKF38393) agonists in primates vs. rodents. Eur J Pharmacol. 1993 Sep 28; 242(2):165-72.
|
|
|
|
|
81.
|
Wyrick SD, Booth RG, Myers AM, Owens CE, Kula NS, Baldessarini RJ, McPhail AT, Mailman RB. Synthesis and pharmacological evaluation of 1-phenyl-3-amino-1,2,3,4-tetrahydronaphthalenes as ligands for a novel receptor with sigma-like neuromodulatory activity. J Med Chem. 1993 Aug 20; 36(17):2542-51.
|
|
|
|
|
82.
|
Watts VJ, Lawler CP, Knoerzer T, Mayleben MA, Neve KA, Nichols DE, Mailman RB. Hexahydrobenzo[a]phenanthridines: novel dopamine D3 receptor ligands. Eur J Pharmacol. 1993 Aug 3; 239(1-3):271-3.
|
|
|
|
|
83.
|
Lawler CP, Gilmore JH, Mooney DH, Mayleben MA, Atashi JR, Mileson BE, Wyrick SD, Mailman RB. A rapid and efficient method for the radiosynthesis and purification of [125I]SCH23982. J Neurosci Methods. 1993 Aug; 49(1-2):141-53.
|
|
|
|
|
84.
|
Gilmore JH, Lawler CP, Eaton AM, Mailman RB. Postmortem stability of dopamine D1 receptor mRNA and D1 receptors. Brain Res Mol Brain Res. 1993 Jun; 18(4):290-6.
|
|
|
|
|
85.
|
Mottola DM, Brewster WK, Cook LL, Nichols DE, Mailman RB. Dihydrexidine, a novel full efficacy D1 dopamine receptor agonist. J Pharmacol Exp Ther. 1992 Jul; 262(1):383-93.
|
|
|
|
|
86.
|
Lovenberg TW, Roth RH, Nichols DE, Mailman RB. D1 dopamine receptors of NS20Y neuroblastoma cells are functionally similar to rat striatal D1 receptors. J Neurochem. 1991 Nov; 57(5):1563-9.
|
|
|
|
|
87.
|
Elsworth JD, Lawrence MS, Roth RH, Taylor JR, Mailman RB, Nichols DE, Lewis MH, Redmond DE. D1 and D2 dopamine receptors independently regulate spontaneous blink rate in the vervet monkey. J Pharmacol Exp Ther. 1991 Nov; 259(2):595-600.
|
|
|
|
|
88.
|
Satoh J, Irino M, Martin PM, Mailman RB, Suzuki K. Neurochemical and immunocytochemical studies of catecholamine system in the brindled mouse. J Neuropathol Exp Neurol. 1991 Nov; 50(6):793-808.
|
|
|
|
|
89.
|
Darney KJ, Lewis MH, Brewster WK, Nichols DE, Mailman RB. Behavioral effects in the rat of dihydrexidine, a high-potency, full-efficacy D1 dopamine receptor agonist. Neuropsychopharmacology. 1991 Nov; 5(3):187-95.
|
|
|
|
|
90.
|
Mileson BE, Lewis MH, Mailman RB. Dopamine receptor 'supersensitivity' occurring without receptor up-regulation. Brain Res. 1991 Oct 4; 561(1):1-10.
|
|
|
|
|
91.
|
Lovenberg TW, Nichols DE, Nestler EJ, Roth RH, Mailman RB. Guanine nucleotide binding proteins and the regulation of cyclic AMP synthesis in NS20Y neuroblastoma cells: role of D1 dopamine and muscarinic receptors. Brain Res. 1991 Aug 9; 556(1):101-7.
|
|
|
|
|
92.
|
Taylor JR, Lawrence MS, Redmond DE, Elsworth JD, Roth RH, Nichols DE, Mailman RB. Dihydrexidine, a full dopamine D1 agonist, reduces MPTP-induced parkinsonism in monkeys. Eur J Pharmacol. 1991 Jul 9; 199(3):389-91.
|
|
|
|
|
93.
|
Bishop JE, Mathis CA, Gerdes JM, Whitney JM, Eaton AM, Mailman RB. Synthesis and in vitro evaluation of 2,3-dimethoxy-5-(fluoroalkyl)-substituted benzamides: high-affinity ligands for CNS dopamine D2 receptors. J Med Chem. 1991 May; 34(5):1612-24.
|
|
|
|
|
94.
|
Martin PM, Irino M, Suzuki K, Lewis MH, Mailman RB. The female brindled mouse as a model of Menkes' disease: the relationship of fur pattern to behavioral and neurochemical abnormalities. Dev Neurosci. 1991; 13(3):121-9.
|
|
|
|
|
95.
|
Brewster WK, Nichols DE, Riggs RM, Mottola DM, Lovenberg TW, Lewis MH, Mailman RB. trans-10,11-dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine: a highly potent selective dopamine D1 full agonist. J Med Chem. 1990 Jun; 33(6):1756-64.
|
|
|
|
|
96.
|
Lewis MH, Gluck JP, Beauchamp AJ, Keresztury MF, Mailman RB. Long-term effects of early social isolation in Macaca mulatta: changes in dopamine receptor function following apomorphine challenge. Brain Res. 1990 Apr 9; 513(1):67-73.
|
|
|
|
|
97.
|
Walker QD, Lewis MH, Crofton KM, Mailman RB. Triadimefon, a triazole fungicide, induces stereotyped behavior and alters monoamine metabolism in rats. Toxicol Appl Pharmacol. 1990 Mar 1; 102(3):474-85.
|
|
|
|
|
98.
|
Herr DW, Mailman RB, Tilson HA. Blockade of only spinal alpha 1 adrenoceptors is insufficient to attenuate DDT-induced alterations in motor function. Toxicol Appl Pharmacol. 1989 Oct; 101(1):11-26.
|
|
|
|
|
99.
|
Jimmerson VR, Shih TM, Maxwell DM, Kaminskis A, Mailman RB. The effect of 2-(o-cresyl)-4H-1:3:2-benzodioxaphosphorin-2-oxide on tissue cholinesterase and carboxylesterase activities of the rat. Fundam Appl Toxicol. 1989 Oct; 13(3):568-75.
|
|
|
|
|
100.
|
Charifson PS, Bowen JP, Wyrick SD, Hoffman AJ, Cory M, McPhail AT, Mailman RB. Conformational analysis and molecular modeling of 1-phenyl-, 4-phenyl-, and 1-benzyl-1,2,3,4-tetrahydroisoquinolines as D1 dopamine receptor ligands. J Med Chem. 1989 Sep; 32(9):2050-8.
|
|
|
|
|
101.
|
Jimmerson VR, Shih TM, Mailman RB. Variability in soman toxicity in the rat: correlation with biochemical and behavioral measures. Toxicology. 1989 Aug; 57(3):241-54.
|
|
|
|
|
102.
|
Lovenberg TW, Brewster WK, Mottola DM, Lee RC, Riggs RM, Nichols DE, Lewis MH, Mailman RB. Dihydrexidine, a novel selective high potency full dopamine D-1 receptor agonist. Eur J Pharmacol. 1989 Jul 4; 166(1):111-3.
|
|
|
|
|
103.
|
Niedzwiecki DM, Cubeddu LX, Mailman RB. Comparative antidopaminergic properties of thioridazine, mesoridazine and sulforidazine on the corpus striatum. J Pharmacol Exp Ther. 1989 Jul; 250(1):117-25.
|
|
|
|
|
104.
|
Niedzwiecki DM, Cubeddu LX, Mailman RB. Comparative anticholinergic properties of thioridazine, mesoridazine and sulforidazine. J Pharmacol Exp Ther. 1989 Jul; 250(1):126-33.
|
|
|
|
|
105.
|
Jimmerson VR, Shih TM, Maxwell DM, Mailman RB. Cresylbenzodioxaphosphorin oxide pretreatment alters soman-induced toxicity and inhibition of tissue cholinesterase activity of the rat. Toxicol Lett. 1989 Jul; 48(1):93-103.
|
|
|
|
|
106.
|
Herr DW, Mailman RB. Buffer effects on high affinity [3H]-prazosin binding in brain and spinal cord. Pharmacol Biochem Behav. 1989 Mar; 32(3):831-4.
|
|
|
|
|
107.
|
Charifson PS, Wyrick SD, Hoffman AJ, Simmons RM, Bowen JP, McDougald DL, Mailman RB. Synthesis and pharmacological characterization of 1-phenyl-, 4-phenyl-, and 1-benzyl-1,2,3,4-tetrahydroisoquinolines as dopamine receptor ligands. J Med Chem. 1988 Oct; 31(10):1941-6.
|
|
|
|
|
108.
|
DeHaven-Hudkins DL, Schulz DW, Walsh TJ, Mailman RB. Responses of dopaminergic and serotonergic systems to triethyllead intoxication. Neurotoxicol Teratol. 1988 Jul-Aug; 10(4):279-85.
|
|
|
|
|
109.
|
Kilts CD, Anderson CM, Ely TD, Mailman RB. The biochemistry and pharmacology of mesoamygdaloid dopamine neurons. Ann N Y Acad Sci. 1988; 537:173-87.
|
|
|
|
|
110.
|
Mailman RB. Mechanisms of CNS injury in behavioral dysfunction. Neurotoxicol Teratol. 1987 Nov-Dec; 9(6):417-26.
|
|
|
|
|
111.
|
Konkol RJ, Chapman L, Breese GR, Collier AM, Kilts C, Finley C, Vogel RR, Mailman RB, Bendeich EG. Hemophilus influenzae meningitis in the rat: behavioral, electrophysiological, and biochemical consequences. Ann Neurol. 1987 Apr; 21(4):353-60.
|
|
|
|
|
112.
|
Crofton KM, Reiter LW, Mailman RB. Pyrethroid insecticides and radioligand displacement from the GABA receptor chloride ionophore complex. Toxicol Lett. 1987 Feb; 35(2-3):183-90.
|
|
|
|
|
113.
|
Mailman RB, Lewis MH. Neurotoxicants and central catecholamine systems. Neurotoxicology. 1987; 8(1):123-39.
|
|
|
|
|
114.
|
Lewis MH, Baumeister AA, Mailman RB. A neurobiological alternative to the perceptual reinforcement hypothesis of stereotyped behavior: a commentary on "Self-stimulatory behavior and perceptual reinforcement". J Appl Behav Anal. 1987; 20(3):253-8.
|
|
|
|
|
115.
|
DeHaven DL, Krigman MR, Mailman RB. Temporal changes in dopaminergic and serotonergic function caused by administration of trimethyltin to adult rats. Neurobehav Toxicol Teratol. 1986 Sep-Oct; 8(5):475-9.
|
|
|
|
|
116.
|
Twery MJ, Kirkpatrick B, Lewis MH, Mailman RB, Cooper CW. Antagonistic behavioral effects of calcitonin and amphetamine in the rat. Pharmacol Biochem Behav. 1986 May; 24(5):1203-7.
|
|
|
|
|
117.
|
Rollema H, Feenstra MG, Grol CJ, Lewis MH, Staples L, Mailman RB. S(-)DP-5,6-ADTN as an in vivo dopamine receptor ligand: relation between displacement by dopamine agonists and their pharmacological effects. Naunyn Schmiedebergs Arch Pharmacol. 1986 Apr; 332(4):338-45.
|
|
|
|
|
118.
|
Napier TC, Givens BS, Schulz DW, Bunney BS, Breese GR, Mailman RB. SCH23390 effects on apomorphine-induced responses of nigral dopaminergic neurons. J Pharmacol Exp Ther. 1986 Mar; 236(3):838-45.
|
|
|
|
|
119.
|
Twery MJ, Kirkpatrick B, Critcher EC, Lewis MH, Mailman RB, Cooper CW. Motor effects of calcitonin administered intracerebroventricularly in the rat. Eur J Pharmacol. 1986 Feb 18; 121(2):189-98.
|
|
|
|
|
120.
|
Mailman RB, Schulz DW, Kilts CD, Lewis MH, Rollema H, Wyrick S. Multiple forms of the D1 dopamine receptor: its linkage to adenylate cyclase and psychopharmacological effects. Psychopharmacol Bull. 1986; 22(3):593-8.
|
|
|
|
|
121.
|
Mailman RB, Schulz DW, Kilts CD, Lewis MH, Rollema H, Wyrick S. The multiplicity of the D1 dopamine receptor. Adv Exp Med Biol. 1986; 204:53-72.
|
|
|
|
|
122.
|
Schulz DW, Stanford EJ, Wyrick SW, Mailman RB. Binding of [3H]SCH23390 in rat brain: regional distribution and effects of assay conditions and GTP suggest interactions at a D1-like dopamine receptor. J Neurochem. 1985 Nov; 45(5):1601-11.
|
|
|
|
|
123.
|
Mailman RB, Kilts CD. Analytical considerations for quantitative determination of serotonin and its metabolically related products in biological matrices. Clin Chem. 1985 Nov; 31(11):1849-54.
|
|
|
|
|
124.
|
Kilts CD, Dew KL, Ely TD, Mailman RB. Quantification of R-(+)-7-chloro-8-hydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-methyl-3- benzazepine in brain and blood by use of reversed-phase high-performance liquid chromatography with electrochemical detection. J Chromatogr. 1985 Aug 9; 342(2):452-7.
|
|
|
|
|
125.
|
Schulz DW, Staples L, Mailman RB. SCH23390 causes persistent antidopaminergic effects in vivo: evidence for longterm occupation of receptors. Life Sci. 1985 May 20; 36(20):1941-8.
|
|
|
|
|
126.
|
Lewis MH, Baumeister AA, McCorkle DL, Mailman RB. A computer-supported method for analyzing behavioral observations: studies with stereotypy. Psychopharmacology (Berl). 1985; 85(2):204-9.
|
|
|
|
|
127.
|
Kilts CD, Knight DL, Mailman RB, Widerlöv E, Breese GR. Effects of thioridazine and its metabolites on dopaminergic function: drug metabolism as a determinant of the antidopaminergic actions of thioridazine. J Pharmacol Exp Ther. 1984 Nov; 231(2):334-42.
|
|
|
|
|
128.
|
Schulz DW, Wyrick SD, Mailman RB. [3H]SCH23390 has the characteristics of a dopamine receptor ligand in the rat central nervous system. Eur J Pharmacol. 1984 Oct 30; 106(1):211-2.
|
|
|
|
|
129.
|
Walsh TJ, Tilson HA, DeHaven DL, Mailman RB, Fisher A, Hanin I. AF64A, a cholinergic neurotoxin, selectively depletes acetylcholine in hippocampus and cortex, and produces long-term passive avoidance and radial-arm maze deficits in the rat. Brain Res. 1984 Oct 29; 321(1):91-102.
|
|
|
|
|
130.
|
DeHaven DL, Walsh TJ, Mailman RB. Effects of trimethyltin on dopaminergic and serotonergic function in the central nervous system. Toxicol Appl Pharmacol. 1984 Sep 15; 75(2):182-9.
|
|
|
|
|
131.
|
Lewis MH, Mobilio JN, Rissmiller DJ, Mailman RB. Thioridazine pharmacodynamics: clinical effects may depend upon drug metabolism. J Am Osteopath Assoc. 1984 Sep; 84(1 Suppl):124-8.
|
|
|
|
|
132.
|
Mailman RB, Pierce JP, Crofton KM, Petitto J, DeHaven DL, Kilts CD, Lewis MH. Thioridazine and the neuroleptic radioreceptor assay. Biol Psychiatry. 1984 Jun; 19(6):833-47.
|
|
|
|
|
133.
|
Mailman RB, Schulz DW, Lewis MH, Staples L, Rollema H, Dehaven DL. SCH-23390: a selective D1 dopamine antagonist with potent D2 behavioral actions. Eur J Pharmacol. 1984 May 18; 101(1-2):159-60.
|
|
|
|
|
134.
|
DeHaven DL, Krigman MR, Gaynor JJ, Mailman RB. The effects of lead administration during development on lithium-induced polydipsia and dopaminergic function. Brain Res. 1984 Apr 16; 297(2):297-304.
|
|
|
|
|
135.
|
Mailman RB, DeHaven DL, Halpern EA, Lewis MH. Serum effects confound the neuroleptic radioreceptor assay. Life Sci. 1984 Mar 12; 34(11):1057-64.
|
|
|
|
|
136.
|
Schulz DW, Mailman RB. An improved, automated adenylate cyclase assay utilizing preparative HPLC: effects of phosphodiesterase inhibitors. J Neurochem. 1984 Mar; 42(3):764-74.
|
|
|
|
|
137.
|
Niedzwiecki DM, Mailman RB, Cubeddu LX. Greater potency of mesoridazine and sulforidazine compared with the parent compound, thioridazine, on striatal dopamine autoreceptors. J Pharmacol Exp Ther. 1984 Mar; 228(3):636-9.
|
|
|
|
|
138.
|
Cooper CW, Twery MJ, Lewis MH, Mailman RB. Anorectic and other behavioral effects of centrally administered calcitonins. Psychopharmacol Bull. 1984; 20(3):451-5.
|
|
|
|
|
139.
|
Hanin I, Krigman MR, Mailman RB. Central neurotransmitter effects of organotin compounds: trials, tribulations and observations. Neurotoxicology. 1984; 5(2):267-77.
|
|
|
|
|
140.
|
Schulz DW, Lewis MH, Petitto J, Mailman RB. Ascorbic acid decreases [(3)H]dopamine binding in striatum without inhibiting dopamine-sensitive adenylate cyclase. Neurochem Int. 1984; 6(1):117-21.
|
|
|
|
|
141.
|
Mailman RB, Lewis MH. Food additives and childhood hyperactivity. Bol Asoc Med P R. 1983 Dec; 75(12):551-3.
|
|
|
|
|
142.
|
Mailman RB, Lewis MH. Food additives and childhood hyperactivity. ASDC J Dent Child. 1983 Jul-Aug; 50(4):283-6.
|
|
|
|
|
143.
|
Lewis MH, Widerlöv E, Knight DL, Kilts CD, Mailman RB. N-oxides of phenothiazine antipsychotics: effects on in vivo and in vitro estimates of dopaminergic function. J Pharmacol Exp Ther. 1983 Jun; 225(3):539-45.
|
|
|
|
|
144.
|
Twery MJ, Cooper CW, Mailman RB. Calcitonin depresses amphetamine-induced locomotor activity. Pharmacol Biochem Behav. 1983 Jun; 18(6):857-62.
|
|
|
|
|
145.
|
Mailman RB, Krigman MR, Frye GD, Hanin I. Effects of postnatal trimethyltin or triethyltin treatment on CNS catecholamine, GABA, and acetylcholine systems in the rat. J Neurochem. 1983 May; 40(5):1423-9.
|
|
|
|
|
146.
|
Nemeroff CB, Luttinger D, Hernandez DE, Mailman RB, Mason GA, Davis SD, Widerlöv E, Frye GD, Kilts CA, Beaumont K, Breese GR, Prange AJ. Interactions of neurotensin with brain dopamine systems: biochemical and behavioral studies. J Pharmacol Exp Ther. 1983 May; 225(2):337-45.
|
|
|
|
|
147.
|
Mailman RB. Lithium-induced polydipsia: dependence on nigrostriatal dopamine pathway and relationship to changes in the renin-angiotensin system. Psychopharmacology (Berl). 1983; 80(2):143-9.
|
|
|
|
|
148.
|
Sonstegard KS, Mailman RB, Cheek JM, Tomlin TE, DiAugustine RP. Morphological and cytochemical characterization of neuroepithelial bodies in fetal rabbit lung. I. Studies of isolated neuroepithelial bodies. Exp Lung Res. 1982 Nov; 3(3-4):349-77.
|
|
|
|
|
149.
|
Widerlöv E, Kilts CD, Mailman RB, Nemeroff CB, Mc Cown TJ, Prange AJ, Breese GR. Increase in dopamine metabolites in rat brain by neurotensin. J Pharmacol Exp Ther. 1982 Oct; 223(1):1-6.
|
|
|
|
|
150.
|
Widerlöv E, Häggström JE, Kilts CD, Andersson U, Breese GR, Mailman RB. Serum concentrations of thioridazine, its major metabolites and serum neuroleptic-like activities in schizophrenics with and without tardive dyskinesia. Acta Psychiatr Scand. 1982 Oct; 66(4):294-305.
|
|
|
|
|
151.
|
Kilts CD, Patrick KS, Breese GR, Mailman RB. Simultaneous determination of thioridazine and its S-oxidized and N-demethylated metabolites using high-performance liquid-chromatography on radially compressed silica. J Chromatogr. 1982 Sep 10; 231(2):377-91.
|
|
|
|
|
152.
|
Mushak P, Krigman MR, Mailman RB. Comparative organotin toxicity in the developing rat: somatic and morphological changes and relationship to accumulation of total tin. Neurobehav Toxicol Teratol. 1982 Mar-Apr; 4(2):209-15.
|
|
|
|
|
153.
|
Kilts CD, Breese GR, Mailman RB. Simultaneous quantification of dopamine, 5-hydroxytryptamine and four metabolically related compounds by means of reversed-phase high-performance liquid chromatography with electrochemical detection. J Chromatogr. 1981 Oct 9; 225(2):347-57.
|
|
|
|
|
154.
|
Abd-Elraof TK, Dauterman WC, Mailman RB. In vivo metabolism and excretion of propoxur and malathion in the rat: effect of lead treatment. Toxicol Appl Pharmacol. 1981 Jun 30; 59(2):324-30.
|
|
|
|
|
155.
|
Frye GD, Chapin RE, Vogel RA, Mailman RB, Kilts CD, Mueller RA, Breese GR. Effects of acute and chronic 1,3-butanediol treatment on central nervous system function: a comparison with ethanol. J Pharmacol Exp Ther. 1981 Feb; 216(2):306-14.
|
|
|
|
|
156.
|
Kuhn CM, Vogel RA, Mailman RB, Mueller RA, Schanberg SM, Breese GR. Effect of 5,7-dihydroxytryptamine on serotonergic control of prolactin secretion and behavior in rats. Psychopharmacology (Berl). 1981; 73(2):188-93.
|
|
|
|
|
157.
|
Vogel RA, Frye GD, Koepke KM, Mailman RB, Mueller RA, Breese GR. Differential effects of TRH, amphetamine, naloxone, and fenmetozole on ethanol actions: attenuation of the effects of punishment and impairment of aerial righting reflex. Alcohol Clin Exp Res. 1981; 5(3):386-92.
|
|
|
|
|
158.
|
Mailman RB, Lewis MH, Kilts CD. Animal models related to developmental disorders: theoretical and pharmacological analyses. Appl Res Ment Retard. 1981; 2(1):1-12.
|
|
|
|
|
159.
|
Mailman RB, Lewis MH. Food additives and developmental disorders: the case of erythrosin (FD&C Red #3), or guilty until proven innocent? Appl Res Ment Retard. 1981; 2(4):297-305.
|
|
|
|
|
160.
|
Ondrusek MG, Kilts CD, Frye GD, Mailman RB, Mueller RA, Breese GR. Behavioral and biochemical studies of the scopolamine-induced reversal of neuroleptic activity. Psychopharmacology (Berl). 1981; 73(1):17-22.
|
|
|
|
|
161.
|
Breese GR, Mueller RA, Mailman RB, Frye GD. Effects of TRH on central nervous system function. Prog Clin Biol Res. 1981; 68:99-116.
|
|
|
|
|
162.
|
Mailman RB, Ferris RM, Tang FL, Vogel RA, Kilts CD, Lipton MA, Smith DA, Mueller RA, Breese GR. Erythrosine (Red No. 3) and its nonspecific biochemical actions: what relation to behavioral changes? Science. 1980 Feb 1; 207(4430):535-7.
|
|
|
|
|
163.
|
Vogel RA, Frye GD, Wilson JH, Kuhn CM, Koepke KM, Mailman RB, Mueller RA, Breese GR. Attenuation of the effects of punishment by ethanol: comparisons with chlordiazepoxide. Psychopharmacology (Berl). 1980; 71(2):123-9.
|
|
|
|
|
164.
|
Vogel RA, Frye GD, Wilson JH, Kuhn CM, Mailman RB, Mueller RA, Breese GR. Attenuation of the effect of punishment by thyrotropin-releasing hormone: comparisons with chlordiazepoxide. J Pharmacol Exp Ther. 1980 Jan; 212(1):153-61.
|
|
|
|
|
165.
|
Mailman RB, Frye GD, Mueller RA, Breese GR. The effects of thyrotropin-releasing hormone (TRH) and other drugs on the actions of alcohol. Adv Exp Med Biol. 1980; 126:509-22.
|
|
|
|
|
166.
|
Frye GD, Vogel RA, Mailman RB, Ondrusek MG, Wilson JH, Mueller PA, Breese GR. A comparison of behavioral and neurochemical effects of ethanol and chlordiazepoxide. Adv Exp Med Biol. 1980; 132:729-37.
|
|
|
|
|
167.
|
Frye GD, Breese GR, Mailman RB, Vogel RA, Ondrusek MG, Mueller RA. An evaluation of the selectivity of fenmetozole (DH-524) reversal of ethanol-induced changes in central nervous system function. Psychopharmacology (Berl). 1980; 69(2):149-55.
|
|
|
|
|
168.
|
Pappas BA, Breese GR, Mailman RB, Mueller RA. Importance of the Locus coeruleus and involvement of alpha-adrenergic receptors in the post-decapitation reflex in the rat. Psychopharmacology (Berl). 1980; 69(2):163-71.
|
|
|
|
|
169.
|
Mailman RB, Breese GR, Krigman MR, Mushak P, Mueller RA. Lead enhancement of lithium-induced polydipsia. Science. 1979 Aug 17; 205(4407):726.
|
|
|
|
|
170.
|
Breese GR, Mueller RA, Mailman RB. Effect of dopaminergic agonists and antagonists on in vivo cyclic nucleotide content: relation of guanosine 3':5'- monophosphate (cGMP) changes in cerebellum to behavior. J Pharmacol Exp Ther. 1979 May; 209(2):262-70.
|
|
|
|
|
171.
|
Breese GR, Lundberg DB, Mailman RB, Frye GD, Mueller RA. Effect of ethanol on cyclic nucleotides in vivo: consequences of controlling motor and respiratory changes. Drug Alcohol Depend. 1979 May-Jul; 4(3-4):321-6.
|
|
|
|
|
172.
|
Harden TK, Mailman RB, Mueller RA, Breese GR. Noradrenergic hyperinnervation reduces the density of beta-adrenergic receptors in rat cerebellum. Brain Res. 1979 Apr 20; 166(1):194-8.
|
|
|
|
|
173.
|
Lundberg DB, Breese GR, Mailman RB, Frye GD, Mueller RA. Depression of some drug-induced in vivo changes of cerebellar guanosine 3',5'-monophosphate by control of motor and respiratory responses. Mol Pharmacol. 1979 Mar; 15(2):246-56.
|
|
|
|
|
174.
|
Mailman RB, Frye GD, Mueller RA, Breese GR. Change in brain guanosine 3',5'-monophosphate (cGMP) content by thyrotropin-releasing hormone. J Pharmacol Exp Ther. 1979 Feb; 208(2):169-75.
|
|
|
|
|
175.
|
Nemeroff CB, Bissette G, Greeley GH, Mailman RB, Martin JB, Brazeau P, Kizer JS. Effects of acute administration of monosodium-L-glutamate (MSG), atropine or haloperidol on anterior pituitary hormone secretion in the rat. Brain Res. 1978 Nov 3; 156(1):198-201.
|
|
|
|
|
176.
|
Mueller RA, Lundberg D, Frye GD, Mailman RB, Breese GR. Cerebellar cGMP varies with motor function and respiratory gas exchange. Neurosci Lett. 1978 Nov; 10(1-2):89-93.
|
|
|
|
|
177.
|
Breese GR, Vogel RA, Kuhn CM, Mailman RB, Mueller RA, Schanberg SM. Behavioral and prolactin responses to 5-hydroxytryptophan in rats treated during development with 5,7-dihydroxytryptamine. Brain Res. 1978 Oct 27; 155(2):263-75.
|
|
|
|
|
178.
|
Mailman RB, Krigman MR, Mueller RA, Mushak P, Breese GR. Lead exposure during infancy permanently increases lithium-induced polydipsia. Science. 1978 Aug 18; 201(4356):637-9.
|
|
|
|
|
179.
|
Mailman RB, Mueller RA, Breese GR. The effect of drugs which alter GABA-ergic function on cerebellar guanosine-3',5'-monophosphate content. Life Sci. 1978 Aug 14; 23(6):623-7.
|
|
|
|
|
180.
|
Breese GR, Mailman RB, Ondrusek MG, Harden TK, Mueller RA. Effects of dopaminergic agonists and antagonists on cerebellar guanosine-3',5'-monophosphate (cGMP). Life Sci. 1978 Aug 7; 23(5):533-6.
|
|
|
|
|
181.
|
Breese GR, Mueller RA, Hollister A, Mailman R. Importance of dopaminergic pathways and other neural systems to behavior and action of psychotropic drugs. Fed Proc. 1978 Aug; 37(10):2429-33.
|
|
|
|
|
182.
|
Mailman RB, Frye GD, Mueller RA, Breese GR. Thyrotropin-releasing hormone reversal of ethanol-induced decreases in cerebellar cGMP. Nature. 1978 Apr 27; 272(5656):832-3.
|
|
|
|
|
183.
|
Konkol RJ, Mailman RB, Bendeich EG, Garrison AM, Mueller RA, Breese GR. Evaluation of the effects of nerve growth factor and anti-nerve growth factor on the development of central catecholamine-containing neurons. Brain Res. 1978 Apr 14; 144(2):277-85.
|
|
|
|
|
184.
|
Longmuir IS, Young A, Mailman R. Induction by hypoxia of a new haemoglobin-like pigment. Adv Exp Med Biol. 1977 Jul 4-7; 94:297-300.
|
|
|
|
|
185.
|
Mailman RB, Barthalmus GT, Muse K, Hodgson E. Multiplicity of hepatic cytochrome P-450 in intact microsomes: effect of phenobarbital induction. Gen Pharmacol. 1977; 8(4):275-9.
|
|
|
|
|
186.
|
Mailman RB, Edmundson W, Muse K, Hodgson E. Multiplicity of hepatic cytochrome P-450 in intact microsomes: effect of 3-methylcholanthrene induction. Gen Pharmacol. 1977; 8(4):281-4.
|
|
|
|
|
187.
|
Mailman RB, Tate LG, Muse KE, Coons LB, Hodgson E. The occurrence of multiple forms of cytochrome P-450 in hepatic microsomes from untreated rats and mice. Chem Biol Interact. 1975 Mar; 10(3):215-28.
|
|
|
|
|
188.
|
Kulkarni AP, Mailman RB, Hodgson E. Cytochrome P-450 optical difference spectra of insecticides. A comparative study. J Agric Food Chem. 1975 Mar-Apr; 23(2):177-83.
|
|
|
|
|
189.
|
Kulkarni AP, Mailman RB, Baker RC, Hodgson E. Cytochrome P-450 difference spectra. Type II interactions in insecticide-resistant and -susceptible houseflies. Drug Metab Dispos. 1974 May-Jun; 2(3):309-20.
|
|
|
|
|
190.
|
Mailman RB, Kulkarni AP, Baker RC, Hodgson E. Cytochrome P-450 difference spectra: effect of chemical structure on type II spectra in mouse hepatic microsomes. Drug Metab Dispos. 1974 May-Jun; 2(3):301-8.
|
|
|
|
|
191.
|
Hodgson E, Philpot RM, Baker RC, Mailman RB. Effect of synergists on drug metabolism. Drug Metab Dispos. 1973 Jan-Feb; 1(1):391-401.
|
|
|
|
|
192.
|
Baker RC, Coons LB, Mailman RB, Hodgson E. Induction of hepatic mixed function oxidases by the insecticide, mirex. Environ Res. 1972 Dec; 5(4):418-24.
|
|
|
|
|
193.
|
Mailman RB, Hodgson E. The cytochrome P-450 substrate optical difference spectra of pesticides with mouse hepatic microsomes. Bull Environ Contam Toxicol. 1972 Sep; 8(3):186-92.
|
|
|
|